Zobrazeno 1 - 10
of 38
pro vyhledávání: '"A. Hamasy"'
Autor:
Arvaddin Hamasy Al Qosam
Publikováno v:
Palapa: Jurnal Studi Keislaman dan Ilmu Pendidikan, Vol 11, Iss 2, Pp 735-754 (2023)
One model that is suitable as a solution for memorizing the Qur'an is the Tikrar Model. One model that is suitable as a solution for memorizing the Qur'an is the Tikrar Model. This pledge model is a model or way of memorizing the Qur'an by repeating
Externí odkaz:
https://doaj.org/article/10e6cd7326034719b0b6f380f6a9b9d9
Autor:
Karin E. Lundin, Qing Wang, Abdulrahman Hamasy, Per Marits, Mehmet Uzunel, Valtteri Wirta, Ann-Charlotte Wikström, Anders Fasth, Olov Ekwall, C.I. Edvard Smith
Publikováno v:
BMC Pediatrics, Vol 18, Iss 1, Pp 1-8 (2018)
Abstract Background A novel immunodeficiency, frequently accompanied by high serum-IgE, and caused by mutations in the PGM3 gene was described in 2014. To date there are no unique phenotype characteristics for PGM3 deficiency. PGM3 encodes a carbohyd
Externí odkaz:
https://doaj.org/article/a6e1df9a6703422893cc377f144f1b9d
Autor:
Lundin, Karin E., Hamasy, Abdulrahman, Backe, Paul Hoff, Moens, Lotte N., Falk-Sörqvist, Elin, Elgstøen, Katja B., Mørkrid, Lars, Bjørås, Magnar, Granert, Carl, Norlin, Anna-Carin, Nilsson, Mats, Christensson, Birger, Stenmark, Stephan, Smith, C.I. Edvard
Publikováno v:
In Clinical Immunology December 2015 161(2):366-372
Autor:
Abdulrahman Hamasy, Olov Ekwall, Qing Wang, C. I. Edvard Smith, Valtteri Wirta, Ann-Charlotte Wikström, Mehmet Uzunel, Karin E. Lundin, Anders Fasth, Per Marits
Publikováno v:
BMC Pediatrics, Vol 18, Iss 1, Pp 1-8 (2018)
BMC Pediatrics
BMC Pediatrics
Background A novel immunodeficiency, frequently accompanied by high serum-IgE, and caused by mutations in the PGM3 gene was described in 2014. To date there are no unique phenotype characteristics for PGM3 deficiency. PGM3 encodes a carbohydrate-modi
Autor:
K E M Blomberg, A. Hamasy, C. I. E. Smith, Anna Berglöf, Mauno Vihinen, Liang Yu, Dara K. Mohammad, Qing Wang
Publikováno v:
Leukemia
Irreversible Bruton tyrosine kinase (BTK) inhibitors, ibrutinib and acalabrutinib have demonstrated remarkable clinical responses in multiple B-cell malignancies. Acquired resistance has been identified in a sub-population of patients in which mutati
Autor:
Berglöf, A.1, Hamasy, A.1, Meinke, S.2, Palma, M.3,4, Krstic, A.5, Månsson, R.5, Kimby, E.6, Österborg, A.3, Smith, C. I. E.1
Publikováno v:
Scandinavian Journal of Immunology. Sep2015, Vol. 82 Issue 3, p208-217. 10p.
Autor:
Lundin, Karin, Wang, Qing, Abdulrahman Hamasy, Marits, Per, Uzunel, Mehmet, Wirta, Valtteri, Ann-Charlotte Wikstrรถm, Fasth, Anders, Ekwall, Olov, C.I. Smith
Table S1. Lab data (Nov 2015, age 24 months). Table S2. Current Gene list for Congenital immune defects (n=305). Figures S1A and B. Alignment of sequences for PCR products from patient and control samples. Figures S2 A and B. Alignment of the sequenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8675bee38b763b7ca7312e36b436ba5a
Autor:
Eva Kimby, Marzia Palma, A. Hamasy, Anders Österborg, C. I. E. Smith, Stephan Meinke, Robert Månsson, Anna Berglöf, Aleksandra Krstic
Publikováno v:
Scandinavian Journal of Immunology
Ibrutinib (Imbruvica™) is an irreversible, potent inhibitor of Bruton's tyrosine kinase (BTK). Over the last few years, ibrutinib has developed from a promising drug candidate to being approved by FDA for the treatment of three B cell malignancies,
Publikováno v:
Scandinavian Journal of Immunology. Aug2013, Vol. 78 Issue 2, p130-139. 10p. 2 Diagrams, 2 Charts.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.